MedEngine, a premium service provider for pharmaceutical and health technology industries, reports a strong financial result in 2017. The company’s revenue grew 61% to 1.6 million euros, which makes MedEngine the fastest growing company in the pharmaceutical and health technology services sector in Finland.1The profit margin before taxes was 20.5%. This was the fourth consecutive year with a profit margin above 20% since the company was founded in 2014.
MedEngine’s core competencies are real-world evidence, medical affairs and marketing services, and business strategy for pharmaceutical and health technology businesses.
“MedEngine combines medical data science expertise and business and marketing know-how with a touch of creativity, in a very unique way”, says Tero Ylisaukko-oja, CEO of MedEngine. “By combining our core competencies, we have been able to create customer projects, which have gained major international recognition. This is reflected in the successful financial results of 2017.”
“Our team consists of young and highly skilled professionals, who have a strong drive for development and growth. We are all committed to developing an agency which provides cutting edge deliverables and five-star customer experience”, says Niina Saarinen, Business Development Director at MedEngine.
MedEngine’s strong growth is expected to continue in 2018 with expanding international operations. “We are still in the very early phases of MedEngine’s development. However, our results in 2017 show that with our unique approach we are able to bring significant value to our customers”, Tero Ylisaukko-ojaconcludes.
Based on most recent publicly available information at asiakastieto.fi on May 21, 2018. Relevant Finnish companies providing clinical research, real-world evidence research, regulatory, market access, medical affairs, medical marketing, and market research services for pharmaceutical industry were included in the reference group.
